Structural factors of rotenone required for inhibition of various NADH-ubiquinone oxidoreductases  by Ueno, Hideki et al.
ELSEVIER Biochimica et Biophysica Acta 1276 (1996) 195 -202 
i ra |  
BB 
Biochi~ic~a et Biophysica A~ta 
Structural factors of rotenone required for inhibition of various 
NADH-ubiquinone oxidoreductases 
Hideki Ueno, Hideto Miyoshi *, Makoto Inoue, Yutaka Niidome, Hajime Iwamura 
Department of Agricultural Chemistry, Kyoto University, Kyoto 606, Japan 
Received 8March 1996; revised 2May 1996; accepted 3 June 1996 
Abstract 
We performed a structure-activity study of a series of synthetic rotenone analogues to elucidate the structural factors of rotenone 
required for inhibition and to probe the structural properties of the rotenone binding site of various NADH-ubiquinone oxidoreductases 
(NDH), including both proton-pumping (NDH-1) and non-proton-pumping (NDH-2) enzymes, from bovine heart mitochondria, potato 
tuber (Solanum tuberosum L.) mitochondria and Escherichia coli (GR 19N) plasma membranes. Using a benzyloxy group as a substitute 
for the E-ring moiety of natural rotenone, systematically selected structural modifications of the A-ring became feasible. The inhibitory 
potency of bovine NDH markedly varied depending upon structural modifications of the A-ring. The native chemical structure 
(2,3-dimethoxy substitution) appeared to be the most favorable for the activity. The spatial ocation of the hydrogen-bond acceptable 
methoxy oxygens may be important for tight fitting into the binding site. However, replacing one of the two methoxy groups by an ethoxy 
group almost completely retained the activity, indicating that the binding environment of the A-ring moiety is spacious enough to 
accommodate a substituent larger than the methoxy group. The manner of action of the derivative lacking the 12-C = O group in the 
C-ring differed from that of natural rotenone, indicating that this functional group is important for supporting the inhibitory action of 
natural rotenone itself. Regarding potato tuber and E. coli NDH-1, the sensitivity of the two enzymes to the inhibition by rotenone 
analogues was much lower than that of the bovine enzyme. The 2,3-dimethoxy substitution was the most favorable for the activity with 
potato NDH-1, whereas this substitution pattern was not necessarily the best with E. coli NDH-1. A rule governing inhibitory potency 
depending upon structural modifications was ambiguous for the two enzymes because of a small variation in the inhibitory potencies. 
These findings indicated that the local binding environment of the A-ring moiety of rotenone in bovine NDH is specific and differs 
considerably from that in potato and E. coli NDH-1. 
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1. Introduction 
Mitochondr ia l  NADH-ub iqu inone oxidoreductase 
(NDH) is a large enzyme that catalyzes the oxidation of 
NADH by ubiquinone coupled to proton translocation 
across the inner membrane. Bovine heart NDH consists of 
over 40 different subunits, noncovalently bound flavin 
mononucleotide (FMN) and at least four distinct electron 
paramagnetic resonance (EPR)-detectable iron-sulfur clus- 
ters [1-4]. This enormous complexity has hampered 
Abbreviations: NDH, NADH-ubiquinone oxidoreductase; NDH-1, 
NDH that bears an energy coupling site; NDH-2, NDH that lacks an 
energy coupling site; PB, 2,3-dimethoxy-5-methyl-6-n-pentyl-l,4-benzo- 
quinone; SMP, submitochondrial p rticles. 
* Corresponding author. Fax: + 81 75 7536408; e-mail: 
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progress in studies into both the pathway of electron flow 
and the mechanism of proton pumping. To characterize the 
structural and mechanistic features of the ubiquinone cat- 
alytic site, specific inhibitors acting at the quinone cat- 
alytic site should be effective probes. There are a number 
of potent inhibitors that act at (or close to) this site [5,6]. 
Among them, commercially available rotenone is the most 
widely applied. However, despite the important role of 
rotenone as a useful inhibitor of this enzyme, the mode of 
inhibitory action of this inhibitor remained to be deter- 
mined. For instance, studies on the site and the stoichiom- 
etry of rotenone binding have yielded puzzling results 
[7-9]. 
Studies of the structural requirements for rotenone in 
the inhibitory action are important for elucidating the 
structural properties of the rotenone binding site and the 
inhibitory mechanism. For this purpose, a structure-activity 
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study of a structurally systematic set of rotenone analogues 
is useful, as shown for other types of electron-transfer 
inhibitors [10-13]. Burgos and Redfeam [14] have shown 
that the bent form of rotenone at the face of contact 
between the B and C rings (i.e., [6a[3, 12al3] configuration, 
Fig. 1) is very important for inhibiting the NDH activity of 
mammalian mitochondria. Using highly purified rotenone 
stereoisomers (5'ix- and 5'13-epirotenones), we confirmed 
this notion and further showed that the significance of the 
stereochemical properties varies with NDH from different 
biological sources [15]. 
Besides the stereochemical properties of rotenone, the 
structural factors required for the inhibitory action remain 
ambiguous ince the structural variations of rotenone ana- 
logues in the structure-activity studies performed so far 
[14,16,17] are limited. In particular, substituent effects in 
the A-ring on the inhibition are entirely unknown, since 
derivatives that possess different substitution patterns in 
the A-ring have not been investigated. This is primarily 
due to the fact that almost all rotenone derivatives used in 
the earlier studies were natural rotenoids and their transfor- 
mation products. Therefore, a study using a systematic set 
of synthetic rotenones i required. However, so long as the 
portion of the rotenone corresponding to the E-ring is fixed 
as the native chemical structure, wide structural modifica- 
tions of the A-ring moiety might be not easy to achieve, 
because of difficulties involved in the stereospecific syn- 
thesis of this moiety (R configuration at the 5'-position) 
[18]. To overcome this obstacle, the E-ring and the at- 
tached isopropenyl group should be replaced by the proper 
mimetic structure which can be synthesized by a simpler 
route. 
In this study, we found that a benzyloxy group can 
functionally substitute for the E-ring moiety of natural 
rotenone. By replacing the E-ring moiety with this sub- 
structure, various modifications of the substitution pattern 
in the A-ring became feasible. To examine the structural 
factors required for the inhibition and to probe the struc- 
tural properties of the rotenone binding site, we compared 
the structure-activity profile of the rotenone analogues 
among various NDH from bovine heart mitochondria, 
potato tuber mitochondria and E. coli plasma membranes. 
2. Experimental procedures 
2.1. Materials 
Antimycin A and deamino-NADH (reduced nicotin- 
amide hypoxanthine dinucleotide) were purchased from 
Sigma. 2,3-Dimethoxy-5-methyl-6-n-pentyl-l,4-benzo- 
quinone (PB) was prepared as described [15]. Rotenol, 
dihydrorotenone and dihydrodeguelin were kindly pro- 
vided by Dr. H. Fukami (Kyoto University). These com- 
pounds were purified before use by silica-gel column 
chromatography and recrystalization from ethanol. Other 
reagents were of the purest grade commercially available. 
2.2. Synthesis 
Rotenone analogues (compounds 1-12, Fig. 1) were 
synthesized based on the procedures for the synthesis of 
(_+)-9-demethylmundeserone reported by Omokawa et al. 
[19]. All synthetic ompounds were characterized by I H 
NMR (Bruker ARX-300), mass spectrometry (JEOL JMS- 
DX300) and elemental analyses for C and H, within an 
error of _+ 0.3%. 
Compounds 1, 2, 3 and 4 were prepared starting from 
commercially available 3,4-dimethoxybenzaldehyde, as 
shown in Scheme 1. In step c, 4-methoxy-2-hydroxybenz- 
aldehyde, 4-ethoxy-2-hydroxybenzaldehyde, 4-benzyloxy- 
2-hydroxybenzaldehyde and 4-(4'-tert-butyl)benzyloxy-2- 
hydroxybenzaldehyde were used to prepare compounds 1, 
2, 3 and 4, respectively. These substituted benzaldehydes 
were obtained by reacting 2,4-dihydroxybenzaldehyde an  
corresponding commercially available alkylchlorides in the 
presence of K2CO 3 and KI in acetone under eflux for 7 h. 
Compound 1, IH NMR (CDC13) ~ 3.76 (s, 3H, OCH3), 
3.80 (s, 3H, OCH3), 3.80 (s, 3H, OCH3), 3.81 (d, J = 4.0 
Hz, 1H, 12a-H), 4.19 (d, J = 12.0 Hz, 1H, 6-H), 4.62 (dd, 
J=  12.0, 3.1 Hz, 1H, 6-H), 4.94 (m, 1H, 6a-H). Com- 
pound 2, IH NMR (CDC13) ~ 1.40 (t, J=  7.0 Hz, 3H, 
OCH2CH3), 3.76 (s, 3H, OCH3), 3.80 (s, 3H, OCH3), 
3.84 (d, J=4 .1  Hz, 1H, 12a-H), 4.02 (q, J=7.0 ,  3H, 
OCI-I2CH3), 4.18 (d, J=  12.0 Hz, IH, 6-H), 4.62 (dd, 
J = 12.0, 3.2 Hz, 1H, 6-H), 4.94 (t, J = 3.1 Hz, 1H, 6a-H). 
Compound 3, IH NMR (CDC! 3) ~ 3.74 (s, 3H, OCH3), 
3.81 (s, 3H, OCH3), 3.87 (d, J = 6.2 Hz, 1H, 12a-H), 4.18 
(d, J=  11.8 Hz, 1H, 6-H), 4.62 (dd, J = 11.0, 3.0 Hz, 1H, 
6-H), 4.95 (t, J = 2.6 Hz, 1H, 6a-H) 5.06 (s, 2H, CH2Ph). 
EI-MS, m/e  418 (M+). Compound 4, IH NMR (CDC13) 
1.31 (s, 9H, C(CH3)3), 3.75 (s, 3H, OCH3), 3.79 (s, 3H, 
OCH3), 3.83 (d, J = 3.6 Hz, 1H, 12a-H), 4.16 (d, J = 12.0 
Hz, 1H, 6-H), 4.60 (dd, J = 12.0, 2.7 Hz, IH, 6-H), 4.91 
(m, 1H, 6a-H), 4.98 (s, 2H, CH2Ph). 
Compounds 5-12 were prepared by the same reaction 
conditions as shown in Scheme 1, but starting from the 
corresponding commercially available substituted benz- 
aldehydes or substituted phenols. In step c, 4-benzyloxy- 
2-hydroxybenzaldehyde was used. The precursors of com- 
pounds 5, 6, 9 and 10 were 4-methoxyphenol, 3-metho- 
xyphenol, 3,4-dimethylphenol and 4-methylphenol, respec- 
tively. The precursors of compounds 7, 8, 11 and 12, 
respectively, were 3,5-dimethoxy, 2,3-dimethoxy, 4- 
ethoxy-3-methoxy and 3-ethoxy-4-methoxybenzaldehydes. 
Compound 5, 1H NMR (CDC13) ~ 3.71 (s, 3H, OCH3), 
3.89 (d, J=2 .1  Hz, 1H, 12a-H), 4.17 (d, J=  13.1 Hz, 
I H, 6-H), 4.62 (dd, J = 13.1, 2.7 Hz, 1H, 6-H), 4.94 (t, 
J = 2.7 Hz, 1H, 6a-H), 5.03 (s, 2H, CHzPh). EI-MS, m/e  
388 (M+). Compound 6, IH NMR (CDC13) ~ 3.72 (s, 3H, 
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Fig. 1. Structure of natural rotenone and the analogues studied here. The shadowed circles in dihydrorotenone, rotenol and dihydrodeguelin represent the 
moieties that differ from natural rotenone. 
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Scheme 1. Reaction conditions. (a) m-C]PhCO3H/EtOAc, (b) HC~CCH2Br, NaT-I/dry THF, reflux 6 h, (c) EtMgBr, 4-substituted-2-hydroxybenzalde- 
hyde/dry THE, (d) H2MnO3/benzene, (e) HCl/],2,4-trichlorobenzene, 220°C 1 h under N 2, (f) CH3COONa/EtOH, reflux 3 h. 
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OCH3), 3.82 (d, J = 7.6 Hz, 1H, 12a-H), 4.20 (d, J = 12.0 
Hz, 1H, 6-H), 4.62 (dd, J=  12.0, 3.0 Hz, 1H, 6-H), 4.91 
(m, 1H, 6a-H), 5.02 (s, 2H, CHzPh). EI-MS, m/e  388 
(M+). Compound 7, 1H NMR (CDC13) 8 3.76 (s, 3H, 
OCH3), 3.79 (s, 3H, OCH3), 4.05 (m, 1H, 12a-H), 4.18 
(dd, J = 20.7, 9.9 Hz, IH, 6-H), 4.36 (dd, J = 7.1, 1.0 Hz, 
1H, 6a-H), 5.03 (dd, J=  18.8, 7.1 Hz, IH, 6-H), 5.08 (s, 
2H, CHzPh) .  EI-MS, m/e  418 (M+). Compound 8, IH 
NMR (CDC13) ~ 3.81 (s, 3H, OCH3), 3.86 (s, shoulder, 
1H, 6a-H), 3.86 (s, shoulder, 1H, 12a-H), 3.87 (s, 3H, 
OCH3), 4.23 (d, J=  12.1 Hz, 1H, 6-H), 4.75 (d, J : 12.1 
Hz, 1H, 6-H), 5.63 (s, IH, 6a-H), 5.63 (s, 2H, CHzPh). 
EI-MS, m/e  418 (M+). Compound 9, 1H NMR (CDC13) 
2.09 (s, 3H, CH3), 2.19 (s, 3H, CH3), 3.83 (d, J = 3.5 
HZ, 1H, 12a-H), 4.18 (d, J = 12.2 Hz, 1H, 6-H), 4.62 (dd, 
J = 12.2, 3.5 Hz, 1H, 6-H), 4.91 (t, J = 3.5 Hz, 1H, 6a-H), 
5.03 (s, 2H, CHzPh) .  EI-MS, m/e  386 (M+). Compound 
10, 1H NMR (CDC13) ~ 2.20 (s, 3H, CH3), 3.88 (d, 
J=3 .5  Hz, 1H, 12a-H), 4.21 (d, J=  11.3 Hz, IH, 6-H), 
4.63 (dd, J = 11.3, 3.5 Hz, 1H, 6-H), 4.93 (t, J = 3.5 Hz, 
1H, 6a-H), 5.03 (s, 2H, CHzPh). EI-MS, m/e  372 (M+). 
Compound 11, IH NMR (CDC13) ~ 1.37 (t, J=  6.7, 3H, 
OCH2CH3), 3.79 (s, 3H, OCH3), 3.83 (d, J = 4.0 Hz, 1H, 
12a-H), 3.96 (m, 3H, OCHzCH3) ,  4.17 (d, J = 12.7 Hz, 
1H, 6-H), 4.62 (dd, J = 12.7, 3.3 Hz, 1H, 6-H), 4.92 (t, 
J = 3.3 Hz, 1H, 6a-H), 5.04 (s, 2H, CHzPh). EI-MS, m/e  
432 (M+). Compound 12, ~H NMR (CDC13) ~ 1.41 (t, 
J = 7.0 Hz, 3H, OCH2CH3), 3.75 (s, 3H, OCH3), 3.88 (d, 
J=  3.9 Hz, 1H, 12a-H), 4.01 (m, 3H, OCH2CH3), 4.15 
(d, J = 12.3 Hz, 1H, 6-H), 4.90 (t, J = 3.0 Hz, 1H, 6a-H), 
5.03 (dd, J = 12.3, 3.0 Hz, 1H, 6-H), 5.03 (s, 2H, CH2Ph). 
EI-MS. m/e  432 (M+). 
Compound 13 was prepared by reducing natural 
rotenone with 10% palladium on carbon in methanol with 
a catalytic amount of HC1 under hydrogen gas at room 
temperature. Compound 13, 1H NMR (CDC13) ~ 3.30 (m, 
1H, 12a-H), 3.81 (s, 3H, OCH3), 3.81 (s, 3H, OCH3), 4.25 
(shoulder, 1H, 6a-H), 4.48 (dd, J=  16.9, 8.7 Hz, 1H, 
6-H), 4.67 (dd, J = 8.7, 5.7 Hz, 1H, 6-H). EI-MS, m/e  
382 (M+). 
The rotenone analogues synthesized in this study except 
compound 13, were a mixture of two stereoisomers (i.e., 
[6a~, 12a~] and [6al3, 12al3] derivatives) which have the 
opposite configuration at the B /C  ring junction. The ratio 
of the stereoisomers checked by using a metal chiral 
HPLC column, Ceramospher RU-1 (4.6 mm × 120 mm, 
Shiseido, Japan), was almost 1 to 1. Since the [6ae~, 12aa] 
derivative is at least 100 times less inhibitory than the 
[6a[3, 12a[3] derivative [15], the inhibition by the former 
was negligible within the applied concentration range. 
To examine the electronic effect of the substituent in 
the A-ring on the inhibition, we tried to prepare derivatives 
which possess electron-withdrawing substituents such as 
chloride and nitro groups. However, the desired products 
were not obtained because of the very low yield in reaction 
step e (Scheme 1), probably due to a decrease in the 
electron density of the A-ring caused by the electron- 
withdrawing substituents. Therefore, all substituents on the 
A-ring of compounds 5-12 were limited to electron-donat- 
ing groups. 
2.3. Assays 
Bovine heart SMP were prepared by the method of 
Matsuno-Yagi and Hatefi [20]. The NADH-PB oxidoreduc- 
tase activity was measured using a stirred cuvette in a 
Shimadzu UV3000 spectrophotometer at 30°C, as the rate 
of NADH oxidation (340 nm, ~ = 6.2 mM- i cm- 1). The 
reaction medium, in a final volume of 2.5 ml, contained 50 
mM potassium phosphate (pH 7.4), 0.25 M sucrose, 1 mM 
MgC12, 2 mM KCN, 0.4 IxM antimycin A and 50 txM PB, 
with a final mitochondrial protein concentration of 30 
ixg/ml. When the effects of the inhibitors were deter- 
mined, SMP were incubated with the inhibitors for 4 rain 
at 30°C in the reaction medium, then the enzyme reaction 
was started by adding 50 IxM NADH. 
Membranes of E. coli (GRI9N) were prepared as de- 
scribed [21]. The deaminoNADH-PB reductase activity of 
NDH-1 was measured as described [15] in a reaction 
medium containing 50 mM phosphate buffer (pH 7.4), 2.5 
mM KCN, 5 mM MgSO 4 and l0 IxM PB, the final protein 
concentration being 15 p~g/ml. The enzyme reaction was 
started by adding 50 txM deaminoNADH. The activity of 
NDH-2 was determined by the same means as that for the 
NDH-I assay, except 50 txM NADH (plus 100 IxM 
rotenone) was added in place of deaminoNADH. 
Potato tuber (Solanum tuberosum, L) submitochondrial 
particles were prepared according to M¢ller et al. [22]. The 
deaminoNADH-PB reductase activity of NDH-1 was mea- 
sured as described [15] in a reaction medium consisting of 
50 mM phosphate buffer (pH 7.4), 0.25 M sucrose, 2 mM 
KCN, 1 mM MgCI 2, 1 I~M antimycin A and 40 txM PB. 
The final protein concentration was 15 ~g/ml.  The en- 
zyme reaction was started by adding 80 ~M deamino- 
NADH. The activity of NDH-2 located inside the inner 
membrane was measured using 80 ~zM NADH (plus 100 
txM rotenone and 0.2 mM EGTA) instead of deamino- 
NADH. 
The stable conformation of synthetic rotenones was 
studied by molecular orbital methods. Computations were 
achieved using a semi-empirical molecular orbital program 
package (MOPAC ver. 6.01) with AM1 parameterization 
[23]. Initial conformations were constructed using standard 
bond lengths and angles. 
3. Results 
3.1. Structure-activity relationship of rotenones with bovine 
heart mitochondrial NDH 
As described in the Introduction, a suitable substitute 
for the portion corresponding to the E-ring and the at- 
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Table 1 
Inhibitory potency (p/5o) of rotenone and synthetic analogues for NADH- 
PB reductase activity 
Inhibitor Pls0 
Bovine NDH potato NDH-1 E. coli NDH-1 
compound 1 6.06 (29) 4.53 (2.0) 4.72 (1.3) 
compound 2 6.62 (8.0) 5.34 (0.30) 5.17 (0.45) 
compound 3 7.92 (0.40) 5.51 (0.21) 4.82 (1.0) 
compound 4 6.59 (8.6) 5.68 (0.14) 4.41 (2.6) 
compound 5 6.82 (5.0) 4.60 (1.7) 5.44 (0.24) 
compound 6 6.01 (33) 4.97 (0.71) 5.30 (0.33) 
compound 7 6.90 (4.2) 4.91 (0.82) 5.08 (0.55) 
compound 8 5.64 (76) 4.93 (0.78) 4.52 (2.0) 
compound 9 6.45 (12) 4.70 (1.3) 5.12 (0.51) 
compound 10 5.82 (50) 5.05 (0.59) 4.84 (0.96) 
compound 11 7.64 (0.76) 4.42 (2.5) 5.00 (0.67) 
compound 12 7.56 (0.92) 5.19 (0.43) 4.52 (2.0) 
compound 13 7.98 (0.35) 5.78 (0.11) 5.11 (0.52) 
natural rotenone 7.96 (0.37) 4.96 (0.73) 4.68 (1.4) 
dihydrorotenone 7.85 (0.47) 4.74 (1.2) 4.59 (1.7) 
rotenol 5.52 (101) < 4.00 ( < 6.7) < 4.00 ( < 6.7) 
dihydrodeguelin 7.61 (0.82) 5.01 (0.65) 4.65 (1.5) 
The proton-pumping NDH was from bovine heart mitochondrial, potato 
tuber mitochondrial nd E. coli plasma membrane. The pls0, the loga- 
rithm of the reciprocal of /50 which is the molar concentration i the 
reaction medium required to reduce the control enzyme activity by 50%, 
was used as an index of inhibitory potency. The plso was measured at 
least twice and the results were averaged. The /50 value is also expressed 
in terms of nmol inhibitor/mg protein for bovine NDH and Ixmol 
inhibitor/mg protein for potato and E. coli NDH-I in parentheses, 
respectively. 
tached isopropenyl group is desired to enable wide struc- 
tural modifications of the A-ring. Therefore, we first syn- 
thesized compounds 1-4 by fixing the substitution pattern 
of the A-ring as that of natural rotenone (2,3-dimethoxy 
substitution). The inhibitory potencies of these inhibitors 
for NADH-quinone (PB) reductase activity are listed in 
Table 1. The pls0, the logarithm of the reciprocal of 150 
which is the molar concentration i the reaction medium 
required to reduce the control enzyme activity by 50%, 
was used as the index of inhibitory potency. The /50 
measurements were repeated at least twice and the results 
were averaged. 
The inhibitory potency in terms of pls0 increased with 
an increase of the hydrophobicity of the portion corre- 
sponding to the E-ring moiety (compounds 1-3). The 
inhibitory potency was entirely retained by replacing the 
E-ring moiety by a benzyloxy group (rotenone vs com- 
pound 3). In addition, the inhibition mechanism of com- 
pound 3 was identical with that of natural rotenone, being 
noncompetitive against exogenous ubiquinone PB [5,9,15]. 
Elongation of this moiety beyond that of compound 3 (a 
benzyloxy group) drastically decreased the activity (com- 
pound 3 vs compound 4), suggesting the existence of steric 
restriction around the portion corresponding to the E-ring. 
These results indicated that a benzyloxy group is a func- 
tionally appropriate substitute for the E-ring moiety. Con- 
sidering that the configuration at the 5'-carbon atom (5'R 
configuration) is important for the activity [15], a high 
rotational freedom of O-CH2-C6H 5 bonds of the benzyl- 
oxy group might make this group suitably fit the binding 
site. 
On the basis of the above findings, the substituents of 
the A-ring were modified by fixing the E-ring moiety as a 
benzyloxy group (compounds 5-12). A lack of one of 
2,3-dimethoxy groups dramatically decreased the in- 
hibitory potency (compound 3 vs 5 or 6), in particular, of a 
methoxy group in the 3-position. Modifying the substitu- 
tion position of methoxy groups also decreased the activity 
(compound 3 vs 7 or 8). Replacing 2,3-methoxy group(s) 
with a methyl group(s) decreased in the inhibitory potency 
(compound 3 vs 9 and 5 vs 10). These findings indicated 
that the native chemical structure (2,3-dimethoxy substitu- 
tion) is the most favorable for tight fitting to the binding 
site. In other words, the portion of the molecule corre- 
sponding to the A-ring is strictly recognized by the binding 
environment. On the other hand, it is notable that replacing 
one of the two methoxy groups with an ethoxy group only 
slightly reduced the inhibitory potency (compound 3 vs 11 
or 12), suggesting that the binding environment of the 
A-ring moiety is spacious enough to accommodate a sub- 
stituent larger than the methoxy group. 
Burgos and Redfearn [14] have studied the effect of 
chemical modifications of the polar 12-C = O group in the 
C-ring on the inhibitory potency. The reduction of this 
group of natural rotenone (conversion 12-C = O to 12-C- 
OH) retained the inhibitory potency, whereas the oxime 
(12-C = N-OH) and methyl (12-C-CH 3) derivatives drasti- 
cally lost the activity. Moreover, although 5'13-epirotenone 
(6act, 12aa-stereoisomer of otenone) was much less po- 
tent than rotenone, the 12-C-OH derivative of 5'13-epi- 
rotenone restored the inhibitory potency. Thus, the struc- 
ture-activity profile for this group was complicated, and it 
is consequently unclear whether or not the 12-C = O group 
is essential for the activity of rotenone. These complex 
results may be attributed to the notion that chemical 
modifications of 12-C = O group bring about a conforma- 
tional change of B /C  ring junction at the same time owing 
to steric congestion arising from the A-ring moiety. We 
therefore synthesized compound 13 to minimize the con- 
formational change. Although the isopropenyl group at- 
tached to the E-ring of rotenone was transformed to the 
isopropyl group in compound 13 during synthetic process, 
effect of this structural modification on the inhibitory 
potency is almost negligibly small, as described later. 
To determine whether or not the conformation of com- 
pound 13 is affected by a lack of the 12-C = O group, we 
performed a conformational study of compound 13. The 
molecular orbital calculation study indicated that the bent 
form is the most stable conformation for compound 13 
(data not shown), as it is for natural rotenone [24,25]. 
Therefore, the effect of a conformational change of the 
B /C  ring junction on the inhibitory potency might be 
200 H. Ueno et al. / Biochimica et Biophysica Acta 1276 (1996) 195-202 
negligibly small, if any. The apparent inhibitory potency of 
compound 13 for NADH-PB oxidoreductase activity was 
almost identical to that of natural rotenone. However, the 
inhibitory action of compound 13 seemed to somewhat 
differ from that of natural rotenone because of the follow- 
ing. (1) The inhibitory potency of compound 13, in terms 
of pls0 value, for NADH-PB oxidoreductase activity was 
almost identical to that for NADH oxidase activity, whereas 
the inhibition by rotenone is less potent for exogenous 
quinone reductase activity than that for NADH oxidase 
activity [5,26]. (2) Although rotenone acts in a noncompet- 
itive manner against exogenous quinone [5,9,15], the inhi- 
bition pattern of compound 13 was competitive against PB 
(data not shown). We therefore concluded that the apparent 
inhibitory potency is indeed retained even in the absence 
of the 12-C = O group, whereas the manner of binding 
somewhat differs from that of natural rotenone. 
Besides the rotenone analogues synthesized in this study, 
we also examined the inhibition using natural rotenoids 
(rotenol, dihydrodeguelin and dihydrorotenone, Fig. 1), as 
shown in Table 1. The inhibitory potency of rotenol, in 
which the whole molecular conformation is not fixed due 
to a lack of C-ring structure, drastically decreased. This 
result supported the earlier conclusion [14,15] that a rigidly 
bent form of rotenone at B/C-ring junction is essential for 
tight fitting into the binding site. The fact that dihydro- 
rotenone retained the activity, indicated that the w-electron 
system of the isopropenyl group attached to the E-ring 
does not contribute to the inhibitory action. The inhibitory 
potency of dihydrodeguelin, which carries geminal methyl 
groups in the position corresponding to the 5'-isopropenyl 
group of rotenone, was about one-half of that of rotenone. 
Since the hydrophobic properties of dihydrodeguelin and 
rotenone or dihydrorotenone are virtually identical, this 
finding also suggested that there is steric restriction around 
the E-ring moiety. 
3.2. Structure-activity relationship of synthetic rotenones 
with potato tuber mitochondrial and E. coli NDH 
We examined the structure-activity profiles for NADH- 
PB oxidoreductase activity of NDH-1 from potato tuber 
mitochondria nd E. coli plasma membranes (Table 1). 
The inhibitory potency of potato NDH- 1 increased with an 
increase of hydrophobicity (or bulkiness) of the E-ring 
moiety (compounds 1-4). The ethoxy group was most 
favorable as a substitute for the E-ring moiety for E. coli 
NDH-1. Thus, although a benzyloxy group was not neces- 
sarily the best substitute for the two NDH-1, the inhibition 
by compounds 5-13 was examined in order to compare 
their structure-activity profile for the two enzymes with 
that for bovine complex I. 
The sensitivity of the two enzymes to the inhibition by 
rotenone and its analogues was much lower than that of 
bovine heart mitochondrial NDH. Compound 3 was 
slightly, but significantly, more potent han natural rotenone 
for the two enzymes. The 2,3-dimethoxy substitution was 
the most favorable for the activity with potato NDH-1, 
whereas this substitution pattern was not necessarily the 
best with E. coli NDH-1. A rule regarding the variation in 
the activity depending upon structural modifications was 
ambiguous because of a small variation in the inhibitory 
potencies. The inhibitory potency of compound 13 was 
about 3 to 6 times larger than that of natural rotenone for 
both enzymes. This result also supported the notion that 
the manner of binding of this inhibitor is not identical with 
that of natural rotenone. 
It is quite likely that the proton pumping machinery is 
close to the ubiquinone binding site [27,28]. We therefore 
compared the sensitivity to the inhibition by rotenone 
analogues between proton-pumping (NDH-1) and non-pro- 
ton-pumping (NDH-2) enzymes. There are two species of 
NDH-2 in the inner membrane of potato tuber mitochon- 
dria [29]. In this study, the NDH-2 which is located on the 
inner surface of the inner mitochondrial membrane was 
assayed in the presence of 100 txM rotenone and 0.2 mM 
EGTA [29]. The NADH-PB oxidoreductase activity of 
NDH-2 from potato tuber mitochondria nd E. coli mem- 
branes was not inhibited in the presence of either analogue 
at a concentration of 100 p~M. Since this concentration 
was nearly at the solubility limit of almost all the test 
compounds, the effect at higher concentrations was not 
examined. The sensitivity to inhibition by natural rotenone 
differs remarkably between NDH- 1 and NDH-2 from potato 
tuber mitochondria [29] and E. coli membrane [15,21]. 
Our results confirmed this notion for a variety of synthetic 
rotenone analogues. 
4. Discussion 
The primary structures of all subunits of bovine heart 
mitochondrial NDH and of many bacterial subunits are 
now known. Functional and biophysical spectroscopic 
analyses of the proton-pumping NDH isolated from bovine 
heart mitochondria [30,31], potato tuber mitochondria [32] 
and E. coli [33] have been reported. However, since 
details of structural features of ubiquinone reduction site 
are still vague, the information obtained from structure-ac- 
tivity studies of specific inhibitor rotenone and its ana- 
logues is helpful at present o predict the manner of the 
interaction between rotenone and its binding site. In partic- 
ular, this kind of information obtained with bovine heart 
mitochondrial NDH is useful, because rotenone is a very 
potent and specific inhibitor of this enzyme, and its in- 
hibitory potency is extremely sensitive even to a slight 
structural change, as shown in this study. 
Using an appropriate model compound of natural 
rotenone and its analogues, we elucidated, for the first 
time, the substituent effects in the A-ring of rotenone on 
the inhibition. To elicit potent inhibition with bovine heart 
mitochondrial NDH, 2,3-dimethoxy substitution in the A- 
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ring was important, indicating that the portion of the 
molecule corresponding A-ring is strictly recognized by 
the binding environment. Specific interactions between the 
hydrogen-bond accepting methoxy oxygens and some hy- 
drogen-bond donating residues may contribute to rotenone 
binding. However, 2,3-dimethoxy substitution is not neces- 
sarily essential for the activity since analogues possessing 
different substitutions did not completely lose the activity. 
In addition, the bulkier ethoxy derivatives retained suffi- 
cient activity. These findings suggested that the ubiquinone 
catalytic site of bovine NDH is spacious enough to accom- 
modate structurally different rotenone analogues in a dis- 
similar manner. This notion is supported by other studies 
[5,13,15,34] of various potent inhibitors of bovine NDH 
(complex I), in which the quinone catalytic site of this 
enzyme was supposed to be a rather large pocket hat can 
accommodate a wide variety of inhibitors in a dissimilar 
l manner . Furthermore, on the basis of a structure-activity 
study of a systematic series of synthetic ubiquinone ana- 
logues, Sakamoto et al. [35] have suggested that the quinone 
catalytic site of this enzyme is a large pocket in which 
bulky quinone analogues can serve as an electron acceptor. 
In this context, from a study using fluorescent probes that 
compete for the binding site of ubiquinone, Ahmed and 
Krishnamoorthy [36] have indicated that the ubiquinone 
binding site of this enzyme has a high level of local 
segmental mobility which enables efficient rotational mo- 
tion of the ligand. 
The apparent inhibition by compound 13 is retained 
even by a lack of the polar and hydrogen-bond acceptable 
12-C = O group, whereas the manner of its action is no 
longer identical with that of natural rotenone. We therefore 
concluded that the 12-C = O group is important for the 
inhibitory action of natural rotenone itself. The earlier 
complicated structure-activity profiles (e.g., Ref. 14) re- 
garding this portion of the molecule would be also ex- 
plained assuming that the rotenone analogues of interest 
interact to the binding pocket in a dissimilar manner 
depending upon the structure of this portion. 
Another study [15] as well as this structure-activity 
relationship study provided information about the struc- 
tural features of the binding site surrounding the E-ring 
moiety. The inhibitory potency of rotenone with bovine 
NDH decreases to about 10% when the 5'R-configuration 
of the isopropenyl group is inverted to a 5'S-configuration 
[15]. Substitute of the E-ring bulkier than a benzyloxy 
group was unfavorable for the inhibition. Furthermore, the 
dihydrodeguelin, a naturally occurring rotenone-related 
compound, was slightly less potent than rotenone. These 
findings indicated that the E-ring moiety is exposed to 
steric restriction arising from the binding pocket. This 
finding provides useful information on the development of
rotenone derivatives carrying a probe. Considering the 
synthetic strategy for introducing some probes into 
rotenone, the E-ring moiety seems to be suitable portion, 
like the synthesis of the photoaffinity-laheled rotenone, 
arylazidoamorphigenin [37]. However, the introduction of 
a bulky probe into the E-ring must be carefully designed 
since the possibility that such a structural modification 
changes the binding manner of the derivative of interest 
from that of natural rotenone cannot be ruled out. Arylazi- 
doamorphigenin elicits very slow kinetics of inhibition 
compared with rotenone (Fig. 3 in Ref. 37). This may he 
due not only to the limited solubility of this compound, as 
claimed by that authors, but also to a change in the manner 
of binding. 
On the basis of the variation in the inhibitory potencies 
of rotenone and its stereoisomers (Yet- and 5'13-epi- 
rotenones), we concluded that the structure of rotenone 
binding sites of bovine heart and potato tuber mitocbon- 
dfial NDH-1 are similar. In other words, both binding sites 
specifically recognize the bent form of rotenone in com- 
mon [15]. This study indicated, however, that variation in 
the inhibitory potency depending upon structural modifica- 
tions of the A-ring as well as E-ring moiety differs some- 
what between the two enzymes, while the 2,3-dimethoxy 
substitution pattern was the best for the activity of both. 
Considering the identical conformation at the B/C-ring 
junction between rotenone and the derivatives synthesized 
here, it is likely that the overall shape of the rotenone 
binding cavities is similar between the two enzymes, 
whereas the local structural nature surrounding the A and 
E-ring moieties differs to some extent. The specific inter- 
actions between the methoxy groups in the A-ring and the 
binding site might be less important in potato NDH-1 than 
that in the bovine enzyme. This would explain the signifi- 
cantly low sensitivity of potato NDH-1 to inhibition by 
rotenone analogues. The structure-activity profiles for 
rotenone stereoisomers a well as for the derivatives yn- 
thesized in this study were totally different between bovine 
heart mitochondrial and E. coli NDH-1, suggesting that 
the structural similarity of the ubiquinone catalytic sites of 
the two enzymes is low. A similar conclusion has been 
obtained from the structure-activity study of a series of 
synthetic apsaicin analogues [13]. 
i We have to mention our ideas concerning the 'quinone catalytic site' 
and the 'quinone binding site'. These two terms are used differently in 
this paper. The quinone catalytic site names generically the reaction site 
which is believed to catalyze the last electron-transfer step from FeS 
cluster N-2 to quinone, and naturally comprises the quinone binding site. 
Since the catalytic site is a rather large pocket as claimed in the text, this 
site accommodates the inhibitors whose binding site do not necessarily 
overlap with that of quinone (see Refs. [5] and [15]). 
Acknowledgements 
We thank Dr. K. Matsushita (Yamaguchi University, 
Japan) for kind advice regarding preparation of the E. coil 
plasma membrane. 
202 H. Ueno et al. / Biochimica et Biophysica Acta 1276 (1996) 195-202 
References 
[1] Ragan, C.I. (1987) Curr. Top. Bioenerg. 15, 1-36. 
[2] Weiss, H., Friedrich, T., Hofhaus, G. and Preis, D. (1991) Eur. J. 
Biochem. 197, 563-576. 
[3] Walker, J.E. (1992) Q. Rev. Biophys. 25, 253-324. 
[4] Ohnishi, T. (1993) J. Bioenerg. Biomembr. 25, 325-329. 
[5] Friedrich, T., Van Heek, P., Leif, H., Ohnishi, T., Forche, E., 
Kunze, B., Jansen, R., Trowitzsch-Kienast, W., Hofle, G., Reichen- 
bach, H. and Weiss, H. (1994) Eur. J. Biochem. 219, 691-698. 
[6] Degli Esposti, M., Ghelli, A., Ratta, M., D. and Estornell, E. (1994) 
Biochem. J. 301, 161-167. 
[7] Ragan, C.I. (1976) Biochim. Biophys. Acta 456, 249-290. 
[8] Singer, T.P. and Ramsay, R.R. (1992) in Molecular Mechanism in 
Bioenergetics (Ernster, L., eds.), pp. 145-162, Elsevier, Amsterdam. 
[9] Heinrich, H. and Werner, S. (1992) Biochemistry 31, 11413-11419. 
[10] Saitoh, I., Miyoshi, H., Shimizu, R. and lwamura, H. (1992) Eur. J. 
Biochem. 209, 73-79. 
[11] Tan, A.K., Ramsay, R.R., Singer, T.P. and Miyoshi, H. (1993) J. 
Biol. Chem. 268 19328-19333. 
[12] Sato-Watanabe, M., Mogi, T., Miyoshi, H., Iwamura, H., Mat- 
sushita, K., Adachi, O. and Anraku, Y. (1994) J. Biol. Chem. 269, 
28899-28907. 
[13] Satoh, T., Miyoshi, H., Sakamoto, K. and Iwamura, H. (1996) 
Biochim. Biophys. Acta 1273, 21-30. 
[14] Burgos, J. and Redfearn, E.R. (1965) Biochim. Biophys. Acta 110, 
475-483. 
[15] Ueno, H., Miyoshi, H., Ebisui, K. and Iwamura, H. (1994) Eur. J. 
Biochem. 225, 411-417. 
[16] Horgan, D.J., Singer, T.P. and Casida, J.E. (1968) J. Biol. Chem. 
243, 834-843. 
[17] Ravanel, P., Tissut, M. and Douce, R. (1984) Plant. Physiol. 75, 
414-420. 
[18] Crombie, L., Freeman, P.W. and Whiting, D.A. (1973) J. Chem. 
Soc., Perkin I, 1277-1285. 
[19] Omokawa, H., Kouya, S. and Yamashita, K. (1975) Agr. Biol. 
Chem. 39, 393-396. 
[20] Matsuno-Yagi, A. and Hatefi, Y. (1985) J. Biol. Chem. 260, 14424- 
14427. 
[21] Matsushita, K., Ohnishi, T. and Kaback, H.R. (1987) Biochemistry 
26, 7732-7737. 
[22] M~ller, I.M., Bergman, A., Gardestrom, P., Ericson, I. and Palmer, 
J.H. (1981) FEBS Lett. 126, 13-17. 
[23] Dewer, M.J.S., Zoebisch, E.G., Healy, E.F. and Stewert, J.J.P. 
(1985) J. Am. Chem. Soc. 107, 3902-2909. 
[24] Adam, D.J., Crombie, L. and Whiting, D.A. (1966) J. Chem. Soc. 
(C) 542-544. 
[25] Carlson, D.G., Weisleder, D. and Tallent, W.H. (1972) Tetrahedron 
29, 2731-2741. 
[26] Gutman, M., Singer, T.P. and Casida, J.E. (1970) J. Biol. Chem. 
245, 1992-1997. 
[27] Yagi, T. (1990)Arch. Biochem. Biophys. 281, 305-311. 
[28] Hofhaous, G., Weiss, H. and Leonard, K. (1991) J. Mol. Biol. 221, 
1027-1043. 
[29] MOiler, I.M. and Lin, W. (1986) Annu. Rev. Plant. Physiol. 37, 
309-334. 
[30] Finel, M., Mark Skehel, J., Albracht, S.P.J., Fearnley, I.M. and 
Walker, J.E. (1992) Biochemistry 31, 11425-11434. 
[31] Finel, M., Majander, A.S., Tyynel~i, J., De Jong, A.M.P., Albrach~, 
S.P.J. and Wikst65m, M. (1994) Eur. J. Biochem. 226, 237-242. 
[32] Lin, T.I., Sled, V.D., Ohnishi, T., Brennicke, A. and Grohmann, L. 
(1995) Eur. J. Biochem. 230, 1032-1036. 
[33] Leif, H., Sled, V.D., Ohnishi, T., Weiss, H. and Friedrich, T. (1995) 
Eur. J. Biochem. 230, 538-548. 
[34] Gluck, M., Krueger, M.J., Ramsay, R.R., Sablin, S.O. Singer, T.P. 
and Nicklas, W.J. (1994) J. Biol. Chem. 269, 3167-3174. 
[35] Sakamoto, K., Miyoshi, H., Matsushita, K., Nakagawa, M., Ikeda, 
J., Ohshima, M., Adachi, O., Akagi, T. and Iwamura, H. (1996) Eur. 
J. Biochem. 237, 128-135. 
[36] Ahmed, I. and Krishnamoorthy, G. (1994) Biochemistry 33, 9675- 
9683. 
[37] Earley, F.G.P. and Ragan, C.I. (1984) Biochem. J. 224, 525-534. 
